Latest Breaking News On - Nvestigational rgnx us75901b1070 - Page 1 : comparemela.com

By Chris Wack Regenxbio said Tuesday that the U.S. Food and Drug Administration has granted a regenerative medicine advanced therapy designation for RGX-121, an investigational one-time AAV. | May 23, 2023

Chris wackDrug administrationDow jonesRegenxbio inc stock exchangePress releaseNvestigational rgnx us75901b1070